AKBA - Earnings call transcript Q3 2024 | Akebia Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and thank you for standing by. Welcome to the Akebia's Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] After the speaker's presentation, there will be a question and answer session. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Mercedes Carrasco, Senior Director of Investor Relations. ahead. go Please

Mercedes Carrasco

detailing welcome section and and a Third XXXX available November Quarter release and financial Thank release our that Update to website. Conference Results is X, Thursday, today, Business issued the that third Call. Financial quarter was results, Investors you, on earlier Akebia's our of Please press note

For website after our be available your convenience, on a replay conclude. of today's call will also we

Erik Chief Ostrowski, have we Butler, Executive Commercial John Officer. Officer; Grund, and Financial Joining me today, Chief Officer; Chief Business and Nick

I'd statements. like those from and results this subject remind includes to actual everyone that materially risks Each call described call this in to uncertainties forward-looking cause differ on that these could forward-looking statements. statement to is

press well issued November and with and recent Additional information describing quarterly in these as Analysis risks most filed is and that results section X on release Management as included annual reports Risk financial the Factors in our Discussion SEC. of we the the

I'd CEO, that, to introduce John like With Butler.

John Butler

and to Thanks, Vafseo team XX bring to thanks, The years working the Akebia us has spent today. past Mercedes, patients. for joining everyone,

So opportunity give stretch update I every the get I the on in we're journey. to progress making of an have I that have home say time to the excited

as momentum January Vafseo (vadadustat), of U.S. we expected significant building market We're in 'XX. for prepare availability of

Our team's X work has yielded initiatives. tremendous progress our on each launch of

driving we're prescriber the demand. at level, First,

and have could of to to benefits focused effectively initiatives demonstrate patients. to progress contracting meaningful with meaningful on for additional we're -- And organizations Vafseo potential Second, that launched third, dialysis share. data generate clinical we've have

Kidney the or from American Nephrology returned ASN I Week. of recently Society

us. a Akebia for across on community, engagement awareness the presence was miss our As advocacy coming I this focused I mentioned out formidable It to and party. building impossible kidney Team Vafseo. previously, had considered

have their takeaways. they new our analyses dialysis for to affairs existing clinical is high. and the ensure Vafseo reviewing medical management and nephrologists are to traffic all-time an they're in heard Here Considering from choice want their the data patients, access. I our over at a and patients that booth, again, Over in anemia my ready on interest for

on physician and Vafseo partners delving and authors time to findings responding into posters data, and X questions. the spent presented We our their

ASN more broader let I'll amongst demand caregivers extremely contracting kidney the overall, prescriber from believe dialysis organizations share support and to to by representatives patient Nick that felt shared have team efforts. detail the Week, updates and regarding important community on Kidney reimbursement, and we Now to from I'm also commercial we optimism groups. Akebia the advocacy kidney and make within our and widespread committed encouraged is we Prior successful. community, I access. Vafseo investigators, and But

we in October, allows reimbursement to codes, and secured organizations TDAPA received or Healthcare In 'XX. reimbursement dialysis we also System which Coding of January HCPCS CMS, Procedure Vafseo for submit Common from

a And for just on use encourage makes the their that of system Vafseo innovative organizations economics to positive dialysis to patients everyone, remind CMS for TDAPA to creates created dialysis. desirable reimbursement formularies. products addition TDAPA

assurance provided the payment this engage further discussions. expectation, by in have contracting While we're pleased receiving as reimbursement TDAPA program our to was we

we efficient codes have to these that are that known begin each Now to organizations account managers ensure our site to educate codes, facilitate can reimbursement. dialysis the at HCPCS key Vafseo

Nick and by on end details XXX% dialysis to purchasing on dialysis through organizations. Vafseo will This access more provide speak providers quarter, to goal our patients securing coverage effort secure group progress supply the of we've year. the also of and made to for with commercial of our nearly contracts

partnership or that Vafseo with hospitalization, educate key use on allow dosing trial, generate Vafseo Finally, we're mortality X times which Vafseo in endpoints, VOICE Outcomes of us to Care, data and In-Center community important plans and September, the further week progressing such can utilization. physician Renal In we support and per data. our on U.S. clinical will new to Experience, generate initiated as

intends study to next across be USRC weeks. and few X,XXX to patients in This the sites, enroll enrolled the we first patient expect

we're evaluating other complementary trials dialysis at initiating organizations. Additionally,

encouraging to among for interest disease. suggests it eager We of can how gain care they DOs patients treatment for understand oral anemia become as help The their the is care to the further will real-world clinical for of standard also additional chronic they're Vafseo our kidney to experience. generating believe new due as improve objective data Vafseo

patients. treatment to dialysis with forward USRC advance and look our bring benefits dialysis working understanding to can closely organizations potential other Vafseo We to additional of

Now we dialysis Kidney with patients nephrologists. population. that on one for for an beyond the treatment with anemia dialysis CKD And is that multibillion-dollar have not opportunity ASN are significant I'll ever need share final Week conversations based on the who more regarding than is represents additional and thought continue to unmet

Vafseo resounding is from That a population. the patient CKD for ASN, reiterated message a our label exploring into expansion at physicians. path we commitment non-dialysis to And

said to we've more update expect As a the previously, the on by provide initiative year. of this we detailed end

to turn about activities. to our commercial talk me Nick let over Now it more

Nicholas Grund

John. Good folks. morning, Thanks,

We to and continue Vafseo market to for foster upon market execute a on strong reception our market enable availability. readiness plans

is sales building HCP education efforts. fact, identification our patient nearly In Awareness, Vafseo. exclusively and focused through is more demand, and on building, team importantly, our

with to received, the us date, we market codes center upon that will to distribution work our a commercial are up HCPCS of at processes believe supply and along for significant we enable significant TDAPA dialysis and have The facilitate we uptake dialysis recently within network. percentage the We set level established commercial hard business drive complete launch. to Vafseo immediately also contracts, at contracts

and XX,XXX independent the small than U.S. centers, current in an contracts To Renal organizations Purchasing specialty with one a many of and group leading Care, the more serves dialysis supply engagement thousands dialysis recently, dialysis patients Group, a serving organization Renal patients, include with U.S. most commercial engagements dialysis the serving our purchasing and organizations. organization of recap, XXX,XXX that of

within have GPOs, organizations on that organizations dialysis treatments commitment purchasing Through the of group and kidney The people share our Vafseo. leaders delivering DOs access process, our and contracts organizations the in living participants with been approximately to disease. active to innovative it's dialysis have with and patients XX% to clear contracting

We approximately of Vafseo WAC $XX,XXX announced year. per the previously

commercial an supply the volume-based decline. and will is coming dynamic welcome, this off-invoice discount are the Our of we volume-based market and price increases, as the decreases, growing. as expected price an share Through and perspective, as Akebia contracts that we use utilization it include Vafseo the if rebates. is a together rebates, Vafseo implies From

essentially the price Vafseo price of In addition, contracts, of line of predictability post the to we when in within with ESAs. be DOs assured expect are TDAPA price the of

our access, and will launch. strategy pricing we This strong have enable a commitment to believe, Akebia to

by to generate populations targeting X TDAPA population expect years and other market the of first the access We availability eligible where is enabled. patient revenue within

increase While just it we potential entire those expect will by expect volume again, TDAPA. for a we offset previously price decrease TDAPA eligible we then in be population, the be a post who targeting will were as XXXX, not patient dialysis

The the today $X is in dialysis alone anemia just management market approximately U.S. billion in

organizations, dialysis of in of the broad patients. Our XXX% goal covering access intent with organizations is to to Vafseo dialysis with nearly place having agreements from enable dialysis

to we supply therapy contracts, We getting compelling on and to is a not have an there with of believe available. additional work commercial need continue goal, over patients XX% to alternative

additional for we in they Auryxia's contracts. upcoming pull can that both the Vafseo phosphate the having along that note additional commercial with binder class, are place TDAPA supply we pursue levers TDAPA I'll as

XXX% demonstrated distribution Dialysis portfolio by are change, there of organizations such, both for as Akebia this across the advantages products to as include contracts are of preparing and date of contracting products. our

supply commercial contract We approach discussions will continue accordingly. our to

So for contracting access, reimbursement Vafseo. ensures for write provides appropriate who the are what prescriptions the coverage, caregivers determine but patients importantly, the will and Vafseo the it's

also prescribers our to end, has progress awareness been that drive good demand. with team making To and connecting

a As XX% to seen increases XX% in X of a use product product result, months use the physicians to intended of have the we launch. the with awareness importantly, intending first and physicians significant of within robust surveyed

expect consistent our they patients Nephrologists use in Vafseo, XXX% measures highest now patients initially. nearly product as home doses to to where on team time of on continue well the expect of devoting focus field to their grow. is sales very are The ESAs. With to we the these as

the are patients. and patients. greatest than will of unmet utilization gaining We expand Vafseo product physicians of attribute the experience with need, the XXX,XXX they believe beyond seeing segments and these after groups total initial more benefits prescribers for where These patient these Vafseo

the only team The is it dialogue broader high or insight with and quality progressed product demonstrated allowed on medical meetings by excitement thoughtfulness, The regarding that Akebia business meaningful type ASN in level additional booth, engagement, our personnel, to the experts the presentation. DO of in goals. and was in theater for John's whether comments

reassuring our more couple commercial nothing engage walking seeing a a waiting deep show trade got And than content. say there's I to and our with a person to and people to attendees into

in pleased are looking Vafseo with the and are board for we X. forward putting in the numbers revenue Overall, quarter on to progress our environment shaping

Let me over Erik. now it turn to

Erik Ostrowski

Thanks, Nick.

working Nick provide excitement in building across a the been team I'll of Vafseo third expressed, initiatives an U.S. and the our incredibly availability externally overview is has and of financial diligently John internally now and As number have both for quarter results. of

revenue net $XX.X third of revenue XXXX. the of of million product compared the as third third $XX.X product to This Auryxia $XX.X XXXX quarter the million $XX consisted in XXXX. during to of of Auryxia Total in of quarter million net was compared million quarter revenue

and with The our decrease contracting by due in increases of volume, reduction was partially primarily third-party payers. offset price execution to a strategy

the net fourth been for this from of expect throughout which overall revenue lower XXXX. of in our is than has despite fact phosphate year, around product level Auryxia the be forward, steady and of will that quarter demand fourth market the revenue believe of product other year, QX net XXXX the Looking binders quarter this we Auryxia we

specifically, dialysis of in wholesalers the TDAPA the being demand. for by from to this for largely More late supply XXXX, organizations, anticipated will stocking will distribution phosphate which disruption This chain decrease is turn in shift ahead driven class we XXXX reimbursement expect to wholesaler away category. binder the broad inventory

the revenue third $X.X compared in compared million License, XXXX $X.X XXXX. of quarter to was quarter collaboration of and the Cost sold of to of XXXX in $XX.X million in other of quarter million at as million in third quarter $XX the third was third XXXX. the goods steady

to due previously a inventory driven our benefit down million ability decrease The by sell inventory. written was commercially as to excess $X.X

expense trials, and compared decreased XXXX quarter by third professional the the in headcount-related in lower costs related quarter certain million which to driven was million XXXX, to clinical expense. consulting the of activities to $XX.X Research decreased and third service of and as of development $X.X completion

to related quarter in increase of incurred quarter product by million in third $XX.X was connection the in with million prelaunch an of expense activities costs XXXX. $XX.X the third driven from Vafseo XXXX, SG&A This increase was availability U.S. the in

lastly, $X.X increase of to $XX.X net termination loss related $XX the net third in quarter in was the settlement XXXX XXXX. of third million in million agreement. with loss the loss in The included million of And liability connection net quarter compared noncash to Vifor royalty in interest expense a the

quarter in the with and have cash with years at runway. consistent ended million least cash We $XX guidance, prior and cash of equivalents X

facility, raised QX, $X.X end million proceeds ATM cash forma bringing pro QX we of net Post in $XX.X million. from to our

I for an force say in availability of Vafseo inventory hand, from view supply point product we established a am positioned financial U.S. stand With well of pleased sales January. to and Vafseo in

questions. that, And welcome we with

Operator

comes Allison Piper [Operator first Our question Instructions] Bratzel from with Sandler.

Allison Bratzel

me. couple for a Just

you label sort of kind defining outcomes we for of on potential expecting? path frame terms regulatory just interactions potential those are to the in expansion interactions the a from of the can kind could update what And nondialysis, range to on of of approval? regulatory of non-dialysis be Just kind what

this but And ASN. think have a in at remarks, really little you like I a prepared big Akebia but then it seems covered presence the did bit,

kind of on to getting Just out there feedback that call docs from stand out? Are that you'd the been hoping any you you've could that. like characterize themes

John Butler

Great. Thanks, Ali.

So the label NDD first on expansion. question

we until It's engage hard kind we year. will to the of say outcome expect to of what So as FDA with this have we've be the engagement. that said,

but our we we clinical is -- so know have get to we and NDD label. do expectation That CRL. work clear want an was And in is what to the

were the risk for makes would they in said like that and look before, So with "Come CRL, right? and where them a that conversation positive," said and discuss engage outlined your group we've the looking we've to to back patient there. benefit sense As is look on believe to that study a we get protocol on and open what are like, what would

to Do that a is alignment study have will want that positively. FDA view But review as issue. say, "Yes, that's that well a I the you'll you you're hope. get like our as And everything be it's right? will and that you not know mean going You I, great. protocol / know to a they always approved," delivering that's

we us, that that that's they amount able of be to deliver describe a the what we for a for data we makes do time, amount the product to will folks, approve have money that And for FDA and sense clinical of reasonable need path a to to hope that to nondialysis. reasonable that can

about I they sort group opportunity. ASN, spoke need. nondialysis there them talked question, to recognize the second every and Again, of unmet we that your patient spoke mean, that mean, leaking a all high into to is they I I individually, at

I'd them FDA engage the well. to So expect with as

forward. how facilitate we'll the exactly -- we little one you. it's be you approval. we to need But -- we'll you're with path then bit And a about do right? them what make get kind That expect to interaction we'll sure with interaction, move delivering feedback, them know just give you clarity interact share they to the never be of what gives it it a to But of some will will and first able be continue when

week. and start, to I'll question, interactions of many over Nick. course second we the so But pass the And I'll the it had

One available. the folks just come we make in of who've the optimism that to this tried make us been with product years to the working through was for script things from

deep I mean in community. roots our are so we this --

to have Vafseo folks us to worked bring hard help many point. so this And

they available. everyone think the was for this product for opportunity have to excited us that I themselves make and

to For yet, sure, have written that a one's we absolutely. right? doesn't mean -- no execute, prescription still I mean

of it investigators to reception done when me up be NDD, groups level to referenced, of with to patient and about talked about part our really the feel up past study about part at committee they've been who we positivity, I we've the think our commitment the studies the steering I and part And we starts who've because But had night. drug. it wanting whether the of that Wednesday talked was or that the of strongly that they that came been came on in KMEs

all other spot had and excitement. launched interactions I mean spot know of I HIF products of positive puts as that well. have a just us in Nick that a of a differentiated without those, I versus and think, commitment kind really lot really But

So it I'll to pass him.

Nicholas Grund

interested question Early No, Ali, Yes. my it's -- year, a great the now. people urgency in than is takeaways X. were are less was Vafseo, see the while in much really you

Now access? their I get Is look like?" the implementing questions that distribution within does it? -- verge something contracted? it's of can it "When granular have they're mean specific the I What center. Do up on Very

the Second, indicate prior prescription I clinical start the specific It's them? of, "What's I therapy?" his so getting to John write When of in?" I How dose? in mentioned should remarks, much patients use do the Very now aren't it stop prepared "Hey, need. to a level do desire you for the think in questions who it we're do

to the I that, shortcomings And that lastly, the therapy. as current also at of care, they're many of therapies. potentially an really were a look physicians need the to standard ESA second for alternative but their of highlighting realizing us They talked

a in forward is that need. need there there's not that a really brought so product is patient need, And also only

So those are my X takeaways.

John Butler

availability right? it sometimes will who launches with you I takes them get numbers, where and time And why nice mean so we nephrology naming just mean physicians some right? to things. through all wade mean, do been this place it's they I -- name still it's -- inactivity a kind of the pre-product -- that have been we've of to Honestly, to but time are I and numbers, to that's have long associated before, described. Nick

Ali? Does that help,

Allison Bratzel

Yes.

Operator

Our Ed H.C. next comes from with question Arce Wainwright.

Antonio Arce

and of for questions the Congrats all recently. then San Diego follow-up. A a good couple maybe me on work at

by Firstly, if certain date in launch of can And release you the supply centers in a approximately much by you're further contracts. XX% get then? at you wondering you how the you mentioned think with dialysis now had your goal mind January? on I'm that

you line to the could weeks. looking of impact And that if around of data, then trial. And and you're sort Wondering in know start VOICE the said of a enrollment you could get secondly, drug launched. few you trial, discuss that once here I time actual prescribing the as how administration

John Butler

Ed. Thanks,

to and I'm do center. it first, to going I'm going to So to one Nick then the talk second the about hand dialysis

on study the and is is VOICE the Block a that. lead which Renal Care U.S. with investigator again, collaborative research Jeff So trial,

we've worked on amazing put years. seen enrolled he's for couldn't He's help And incredibly of worked working studies He us. professional very, excited XX-something together a Really that Jeff happier with with very be organization. he enrollment. an about I I've gets -- the trial trialist. and runs this I've Jeff was with with to efficiently, some materials

guess, the weeks. we enrollment. this But enrolled criteria, exclusions for mean see quick first few few very I hope so inclusion to as the that. said, patient it's I next broad I expect patients that very dialysis, on is a -- within We

it there's last talked least in at will goal outcome be right? set or to completed, follow-up. study, is patient fully an The we the about an of we but patient enrolls So have of -- a after everyone amount the when it that study haven't enrolled -- amount is expect follow-up every

the right? X the study is, So a, dosing, think times -- about it's goal but using as we weekly

about think using this very protocols others -- USRC dosing of dosing probably regimen And using the how will when provider that dialysis that. USRC see is that with comfortable experience successfully. significant amount So at think a beyond we significant regimen, they and investigators that that makes impact gives that USRC

important have very think that So a impact. will near-term we

But X get study benefit. generate the to TDAPA At to entire doing lower fish the the show to years, right? the will reimbursement. reason population now the we this will, be I we're got if mean we price pond, have years entire we've of X data to in we us. will And those that think is available But that Vafseo. you of dialysis the it, of a about believe end

how for experience it the -- patients the well there's we get it a it about They way works They those where physicians like benefit. TDAPA is in see We think using patients. product.

Then you really non-dialysis becoming that market when penetrating significantly. care, have patients step dialysis, next allows then of is generate additional the that you data quite on positive that of standard step and Then approval. third arrive they on arrive Vafseo. And

quickly. TDAPA this data the or getting X again, supposed And isn't But soon from VOICE So on before -- really move we we quickly X possible depends that's expect one study dialysis after enroll. This period to the last mix. as years. or as ends quite a contracting how that it will is

Nicholas Grund

Yes.

As now. -- sound you about XX% lacking might A it's said, we're Ed, humility. goal this at like

Our is to goal hit XXX%.

X it's the during from use things. CMS, of reimbursement a in supports One, period. drugs that mechanism TDAPA, the X-year innovative based on really there's important And place

Second, post or And the we've our the created during pricing strategy. strategy ESA to our to good predictability TDAPA We've importantly, through similar product. for very created matching around pricing. a period economics allow should have being that pricing DOs TDAPA

and patients to And are those none need. gives opportunity Over to we getting that then unless those Vafseo There patients of goal a care" not things on "standard is clinical clinical get of still XX% believe lastly, need. matter a goal. really to an there's of today's

John Butler

whom under is there about providers, XX%. are XXX% Remember, X represent have contract absolutely who our one already goal. of we So

our a you So where know of are focused. lot efforts

follow-up to quick study. one clarify the just on VOICE And

to the publication. day. We accepted FOCUS It's any have for -- been have recall, which expect published we study, be we

We that, to and have We sufficient be that to added expect day online our it now. to label. any TIW work dosing is go think the FDA the to

them about to be will have we TIW and the talk decision strategic to will that that and NDD FDA after, as experience. about help product first go post the VOICE to we expand -- study access need generate We the providers the do FOCUS made as we've But really a dialysis we more way to Recall, getting then TDAPA. data think think publication to on approval. focus don't for

Antonio Arce

-- then made as they we you've include you've I can that just if Vafseo are both follow-up. right. I'm you XXX% look the All efforts those possible. now, And as you signed the right mentioned and coming noticed one levels around previously soon, that DOs of generics with discuss and of pretty revenue Great. close contracts in the as point to Auryxia maintaining what wondering now Auryxia the to

John Butler

an important us. because talk for place. been -- us. part allowed important it. contracts discussions a with us in the these providers of kind It's contracting been has such enabled Auryxia has put past needed And for Nick and to contracting to Vafseo of in Yes. of Auryxia about referenced it has year really Dialysis lot get for incredibly they

and and branded -- number process We addition -- so are have about are those with X bundle binders that products Auryxia again, bundle for of thinking at contracts in place. cinacalcet they that we looking that a the that have providers of that happened added end the X-year know to of years We the and there's that at those Parsabiv process. the to kind larger using

no that exactly know in were not been have the happen mean there time. for X ANDA to filers. filers I point ANDA this with approved at There's going do We what's conditionally right? Auryxia, ANDAs

anyone, don't the of if course. know introduce at of we So end who's March, going to products

your first got an generally authorized generic. You've filer

be So it limited XXXX. most will of competition for

for that a to access I on allows branded us think basis. Auryxia maintain stronger

quarter of think very pieces there's for we opportunity. 'XX. it we about the that, But as conservative the All 'XX. before end great We're 'XX even and of those 'XX, think put towards of fourth call together

Nick, there to way our if price, at that's a if maintain able if because I to contracts anything power to. lower is we're we've that choose And there's we built the add important portfolio. even don't that And And revenue there. -- know is in

Nicholas Grund

predictability all. the it again, you to that due being having provide competition. generic that can price to be, with think opportunity reduce I manufacturer I we the branded mean, need and had if our that to it's No,

them allows switch time. over spend It cost operational to go generics and protocol into come not their marketplace to to enter formulation generic a and and the the into have

a there generic it ability to think the bit process, the be you of peace that throughout the if will. of provides I have DOs mind with we

John Butler

We're there as is and a we providers driving mean, Auryxia. for by value Vafseo, being partner with term. dialysis term, that long know growth Akebia the driven right, Auryxia, long I the the of we're Again,

I product mean this product, -- to is a growth, right? They it Vafseo -- great a need I They place, support hate to contracts to we're in think and mean there to able say a is them that. it enable Auryxia they of through formulary. this have on that I to it way, want to it's but want as be use. I tool something

that believe help to the them decision to we incorporate And will well. make Vafseo as

longer of it's strategic growth very story So term. but a part of commercial important our thinking, not our part

Operator

BTIG. comes Our with Julian from Harrison next question

Julian Harrison

the Congrats on segment Vafseo. is contracting that? than to on Is dialysis It's all Higher it approximately percent for the approximately of share what at great front XX%? momentum. I'm able or lower contracted the the home see to progress you're time? this if wondering

would be helpful for programs in to any your you soon are early-stage now then as be plan INDs, well. that could efforts? remaining like to first And clinic the guidance the about acute you also If for talk injury, kidney for how giving those steps you

John Butler

question? home the Nick,

Nicholas Grund

Yes.

changes included as both so dialysis all in-center of well home home little while in in the each as organization bit, percent a contracts. our population And are the the

of So none contracts our excluded.

we the Ultimately, mind we protocols. and talk high-dose suggested, to it come the writing the is the to, come home/PD to when will ESA. X physicians down as populations certainly But that population

probably in we between little home difference and on in-center. reality, and how that have that the percentage, so very there's the up splits approximately, between XX% And overall

John Butler

for Thanks that.

that on question so to we need our early as everyone's know launch, is that our Vafseo well, We well. much it's do and programs. know I So a focus for thanks Julian, the right? incredibly focus on

the time, really early-stage lot same we at our the But excited the really growth will about future and of company what future. think our we're about programs, in fuel and of the growth kind a

kind the is which pre-IND that before. clinic AKB-XXXX, cetera. program. in early-stage be tox work, next for year, et that. We development so goal seem to have end track we're in is of our the And as It's referenced, of it AKI on now, we've before an And you doing to program the said

hold we're always have quite to but you kind tight, about that. So of on excited

And then, cetera. retinopathy which course, et if doing equally, of excited product work, CMC XXXXX, of XXXX, in more our that not behind program moving is I'm we're about, but forward prematurity,

in of the that the that just advisory on an product could Burke, ago, couple Steve were neonates. board had texting And population about XXXXX We meeting to have on we opportunity retinopathy remember prematurity how talking have of a our during move excited I faster. guess, of now. months I about CMO, meeting, folks These so just

excited can clearly next to after I we not going one as really question. year, but But hopefully, move about But forward. be moving in XXXX we're So clinic one that as is that it. that appreciate soon the

Operator

John question-and-answer turn back Butler, CEO, now to I concludes This would the remarks. closing it like to for session.

John Butler

and well our going running a very In operator. we're when start well, Vafseo contracting Thanks, available is summary, extremely for is in positioned January.

hitting commercial long-term I'm and pleased every today. success on our near- The been Vafseo on execute metric. of we've say we internal discussed hinges to ability initiatives these on to But

on progress forward our look many look you San to Francisco We in in forward January. during and updating investor our to you later then. of then meetings We year this seeing

Have a day. everyone. great Thanks,

Operator

conference participating. call. concludes you This for today's Thank

You now may disconnect.

Akebia Therapeutics (AKBA) 7 Nov 242024 Q3 Earnings call transcript